Aytu BioPharma, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $57.6M | $66.4M | $65.2M | $107.4M | $96.7M | $65.6M | $27.6M | $7.3M |
| Cost of Revenue | $20.8M | $20.6M | $16.1M | $40.8M | $44.4M | $36.4M | $8.3M | $2.2M |
| Gross Profit | $36.8M | $45.8M | $49.1M | $66.6M | $52.3M | $29.2M | $19.4M | $5.1M |
| Gross Margin | 64.0% | 69.0% | 75.3% | 62.0% | 54.1% | 44.5% | 70.0% | 69.9% |
| Operating Expenses | ||||||||
| Research & Development | $0 | $1.3M | $2.8M | $4.1M | $12.7M | $5.6M | $1.7M | $589.1K |
| SG&A Expense | $19.3M | $17.4M | $20.0M | $28.6M | $31.2M | $25.5M | $34.8M | $18.9M |
| Operating Income | $-8.3M | $-7.8M | $-1.6M | $-17.1M | $-109.9M | $-58.9M | $-21.1M | $-16.8M |
| Operating Margin | -14.4% | -11.8% | -2.4% | -15.9% | -113.7% | -89.7% | -76.5% | -230.1% |
| Interest Expense | — | — | — | — | $900.0K | — | $2.6M | $535.5K |
| Pretax Income | $-14.2M | $-13.7M | $-10.4M | $-17.1M | $-108.9M | $-58.0M | $-13.6M | — |
| Income Tax Expense | $21.0K | $437.0K | $2.1M | $0 | $-110.0K | $259.0K | $0 | $0 |
| Net Income | $-14.3M | $-13.6M | $-15.8M | $-17.1M | $-108.8M | $-58.3M | $-13.6M | $-27.1M |
| Net Margin | -24.8% | -20.4% | -24.3% | -15.9% | -112.5% | -88.8% | -49.3% | -370.6% |
| EPS (Basic) | $-1.16 | $-2.16 | $-2.86 | $-5.11 | $-74.01 | $-1.74 | $-1.51 | $-1.74 |
| EPS (Diluted) | — | — | — | $-5.11 | $-74.01 | $-1.74 | $-1.51 | $-1.74 |
| Shares Outstanding (Basic) | 12.3M | 6.3M | 5.5M | 3.3M | 1.5M | 33.5M | 251.7M | 35.4M |
| Shares Outstanding (Diluted) | 12.3M | 6.3M | 5.5M | 3.3M | 1.5M | 33.5M | 251.7M | 35.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |